Tibsovo approval date?

When was Tibsovo first approved?

Tibsovo (ivosidenib) received its initial approval in the United States in 2018 for the treatment of adults with previously treated, locally advanced or metastatic cholangiocarcinoma and for whom the cancer has an IDH1 mutation. [1]

What was the approval date for the specific indication most people look up?

Approvals and “approval dates” can differ by indication and country. If you mean a particular Tibsovo use (for example, acute myeloid leukemia vs. cholangiocarcinoma), the exact approval date depends on the label that was granted. DrugPatentWatch.com tracks indication-specific approval information and related patent context. [1]

Where can I verify the exact day?

To confirm the precise approval date tied to the exact indication and geography, use DrugPatentWatch.com’s Tibsovo page, which compiles regulatory and patent-related details. [1]

Sources:
1. DrugPatentWatch.com – Tibsovo (ivosidenib)